Navigation Links
Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
Date:1/15/2008

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today the successful completion of a Phase Ib clinical study of TRX1, a novel humanized anti-CD4 monoclonal antibody (MAb), in subjects with refractory cutaneous lupus erythematosus (CLE). The Phase Ib study was designed to assess the safety, tolerability, and pharmacokinetics of TRX1. Tolerx has received a milestone payment from Genentech, Inc. in conjunction with the completion of this study.

Tolerx and Genentech entered into a collaboration in 2002 to develop and commercialize certain anti-CD4 monoclonal antibodies, including TRX1. Pursuant to this arrangement, Genentech may undertake the further development, manufacturing, and commercialization of those anti-CD4 molecules in any indication. The agreement provides for Tolerx to potentially receive development and regulatory milestone payments. In addition, Tolerx can receive royalties on worldwide net sales of those anti-CD4 antibodies and has the option to participate in a loss and profit sharing arrangement with Genentech in the United States.

Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx, commented, "This is an exciting next step in our effort to define new treatment paradigms for patients afflicted with immune-mediated diseases. The clinical data from the Phase Ib study provides us with optimism for the continued advancement of our anti-CD4 antibody programs, and we remain excited about our collaboration with Genentech."

About TRX1

TRX1 is a novel humanized monoclonal antibody (MAb) that binds to the CD4 receptor found on both T effector cells and T regulatory cells. TRX1 is expected to block the activation and function of T effector cells and to favor dominance of T regulatory cells. This process, referred to as down regulation of the immune system, results in hyporesponsiveness, or tolerance, to antigens. In a preclinical study in a primate model, administration of TRX1 during the development of a primary immune response to a foreign protein, or antigen, resulted in longstanding and specific tolerance to that antigen. This type of suppression of the immune system may have therapeutic benefit in treating autoimmune diseases that occur when the human immune system mistakenly identifies the components of the human body as foreign.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of patients with immune- mediated diseases. In addition to the development of TRX1, Tolerx is currently developing otelixizumab, an anti-CD3 MAb, in type 1 diabetes with its collaboration partner, GlaxoSmithKline. Tolerx is also engaged in preclinical development of new MAb product candidates that engage the body's immune system and further promote and enhance immune responses. This type of therapy is being researched for the treatment of cancer and chronic viral diseases.

Safe Harbor Statement

This press release contains certain statements that are preceded by, followed by, or that include the words "if," "will receive," "is expected to," "may have" or similar expressions or the negation thereof. Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding Genentech's activities with respect to further development of TRX1, the potential value of payments that may be received by Tolerx pursuant to the agreement with Genentech, and the anticipated progress and development of TRX1 are all forward-looking statements. Such forward- looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors and risks that may affect the forward-looking statements include the results of future clinical studies, the ability to obtain regulatory approvals for TRX1 and the introduction and impact of competing therapies by other companies. These statements reflect the view of Tolerx as of the date of this press release, and Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
2. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
3. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
4. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
5. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Medarex to Receive Milestone Payment from Amgen
8. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
11. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8. Februar 2016  LivaNova, PLC, Hersteller ... Infografik mit dem Titel „Epilepsy Around the ... der der Krankheit gegenüber ein größeres Bewusstsein ... soll, Medikamentenresistenz bei Epilepsie auf dem Internationalen ... zu machen. Mithilfe der neuen Infografik sollen ...
(Date:2/5/2016)... Va. , Feb. 5, 2016  ivWatch, a medical ... Virginia Outstanding STEM Award granted by Governor Terry McAuliffe,s ... Science Innovation on February 25th at an event to be ... . The STEM award honors professionals and business that have ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at Source Capital Group,s 2016 Disruptive Growth & ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. ... place at 3:15 p.m. ET. http://www.aethlonmedical.com .  The ... the conclusion of the live event. The panel discussion will ...
Breaking Medicine Technology:
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some ... to Perry A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay ... and detoxifying the body. , A former motivational speaker, Perry A~ has since dedicated ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide variety of organizations. DocuSyst provides a cloud hosted environment for ... Some installations include integration with various 3rd party applications using the FileHold web ...
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
Breaking Medicine News(10 mins):